Clinical trial · no report yet · Phase 3
NCT04987203
Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
- NCT04987203 ↗
- Completed
- AVEO Pharmaceuticals, Inc.
- 186 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 97 | |
| YouTube | 56 | |
| Podcasts | 30 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Tivozanib; Nivolumab
- Arms
- Tivozanib in Combination with Nivolumab · Experimental
- Tivozanib · Experimental
- Enrollment
- 343
- Primary outcomes
- Progression free survival
- Sponsor
- AVEO Pharmaceuticals, Inc. with Parexel, Bristol-Myers Squibb
- Start
- Sep 9, 2021
- Primary completion
- Jan 20, 2026
- Results posted
- No
- Registry record
- NCT04987203 · updated May 8, 2026
Publications
linked from the registry- Choueiri TK, Albiges L, Barthelemy P, Iacovelli R, Emambux S, Molina-Cerrillo J, Garmezy B, Barata P, Basu A, Bourlon MT, Moon H, Ratta R, McKay RR, Chehrazi-Raffle A, Hammers H, Heng DYC, Braendle E, Beckermann KE, McGregor BA, Motzer RJ. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study. Lancet. 2024 Oct 5;404(10460):1309-1320. doi: 10.1016/S0140-6736(24)01758-6. Epub 2024 Sep 13. PubMed 39284329
- Yang Y, Psutka SP, Parikh AB, Li M, Collier K, Miah A, Mori SV, Hinkley M, Tykodi SS, Hall E, Thompson JA, Yin M. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Cancer Med. 2022 Aug;11(16):3106-3114. doi: 10.1002/cam4.4679. Epub 2022 Mar 18. PubMed 35304832